Printer Friendly

ANTIBODY PRODUCTION ADVANCE REPORTED AT AMERICAN CHEMICAL SOCIETY MEETING

 ANTIBODY PRODUCTION ADVANCE REPORTED AT
 AMERICAN CHEMICAL SOCIETY MEETING
 BERKELEY, Calif., April 8 /PRNewswire/ -- Breakthroughs in the production of engineered antibody fragments through direct expression in microorganisms were presented today to the annual meeting of the American Chemical Society (ACS) in San Francisco.
 In an invited presentation to the ACS meeting, Marc Better, Ph.D., director of Molecular Genetics at XOMA Corp. (Berkeley and Santa Monica, Calif.) (NASDAQ/NMS: XOMA), reported high level expression in E. coli of antibody fragments Fab' and F(ab')2 from a human-like version of the murine H65 monoclonal antibody. Microbial expression of antibody fragments by direct secretion from E. coli offers at least two important advantages over previous production methods. Antibody fragments are produced in high yield and are properly folded. XOMA technology allows cost-effective production of material which is more homogeneous than antibody fragments produced from whole antibodies.
 H65 is the monoclonal antibody portion of XOMA's CD5 Plus(TM) product. E. coli-produced H65 fragments retain target specificity and can be formulated into highly potent immunoconjugates.
 Antibodies and antibody fragments are useful targeting agents for treatment and diagnosis of human disease. XOMA scientists were the first to demonstrate efficient production of antibody fragments in the E. coli in a report in Science (Better, et al., 1988) and in the yeast Saccharomyces in the Proceedings of the National Academy of Sciences, U.S.A. (Horwitz, et al., 1988). More recently, XOMA scientists have evaluated immunoconjugates with bacterially produced antibody fragments and developed the technology to produce this material for potential therapy in human disease.
 XOMA has several issued patents and applications pending covering aspects of its antibody and immunoconjugate technologies. In July 1991, XOMA was issued U.S. patent No. 5,028,530 for novel technology for the production of genetically engineered proteins such as antibody fragments in bacteria. In March, U.S. patent No. 5,093,475 was issued to XOMA for the use of a series of novel reagents in immunoconjugate development.
 XOMA Corp. is a leading company in the development of therapeutic products using monoclonal antibody and recombinant DNA technologies.
 -0- 4/8/92
 /CONTACT: Carol D. DeGuzman of XOMA Corp., 510-644-1170; or Diana Dalsass or Mike Millican of Robert Marston and Associates, 212-371-2200, for XOMA Corp./
 (XOMA) CO: XOMA Corp. ST: California IN: MTC SU:


TS -- SF006 -- 6093 04/08/92 09:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1992
Words:393
Previous Article:HOMEFED ANNOUNCES FIRST QUARTER EARNINGS
Next Article:FIRST LOW-LOAD DISABILITY INSURANCE POLICY FOR INDIVIDUALS AVAILABLE VIA FEE FOR SERVICE, INC.
Topics:


Related Articles
DOW CORNING'S McKENNON AWARDED CHEMICAL INDUSTRY GOLD MEDAL
Nalco Chemical Company to Receive Presidential Award for Environmental Innovation.
Merck KGaA and ProMetic Establish Strategic Alliance for Monoclonal Antibody Purification.
ProMetic Technology Reaches New Milestones For Monocloral Antibody (MAb) Purification; - Platform for MAb purification exceeding expectations - First...
Dow and Sunol to Collaborate in Plant-Based Production of Antibody For Treating Cancer; Studies will compare plant-based and mammalian cell...
BIO Announces New International Conference: The World Congress on Industrial Biotechnology and Bioprocessing.
Cambridge Antibody Technology and Lonza Extend Manufacturing Agreement.
Wyeth Oncology Researchers Honored with ACS Heroes of Chemistry Award.
Sumitomo Chemical Issues 2008 CSR Report, 'Sustainable Chemistry'.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters